CaSRevolution is developing disease-modifying therapies for neurodegenerative diseases using a novel approach that targets underlying biological mechanisms. The company aims to improve patient outcomes by addressing the progression of conditions such as Alzheimer's and Parkinson's through its innovative drug discovery platform.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's lack effective treatments that can halt or reverse disease progression. Current therapies primarily address symptoms, failing to target the underlying biological mechanisms driving neuronal damage and cognitive decline. This leaves a significant unmet need for disease-modifying interventions.
Solution
CaSRevolution is developing a novel therapeutic approach to combat neurodegenerative diseases by targeting the fundamental biological processes that contribute to their development and progression. Their innovative drug discovery platform aims to identify and develop therapies that can modify the course of diseases like Alzheimer's and Parkinson's, rather than merely alleviating symptoms. By addressing the root causes of neurodegeneration, CaSRevolution seeks to improve patient outcomes and potentially offer a more effective long-term solution.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases, their families, and healthcare providers specializing in neurology and geriatric care.
Features
- Innovative drug discovery platform targeting underlying biological mechanisms of neurodegeneration
- Focus on disease-modifying therapies for Alzheimer's and Parkinson's diseases